Clinical trials · source year
44 selected, source-linked clinical trial records dated 2024. This is selective source coverage, not a complete timeline.
44 selected records.
17 connected profiles.
44 distinct public records.
Cited chronology
Lixisenatide
PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT01950403 at 2026-07-30T18:37:14.701Z. Its registry update date was 2024-12-09, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04966741 at 2026-07-30T18:38:25.516Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT03965130 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04943068 at 2026-07-30T18:38:25.522Z. Its registry update date was 2024-11-13, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT06519656 at 2026-07-30T18:39:33.787Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT03471728 at 2026-07-30T18:39:33.779Z. Its registry update date was 2024-10-18, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05709444 at 2026-07-30T18:39:33.780Z. Its registry update date was 2024-10-17, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06498063 at 2026-07-30T18:42:56.616Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Plecanatide
PeptideScanner retained ClinicalTrials.gov record NCT05151328 at 2026-07-30T18:42:56.581Z. Its registry update date was 2024-07-11, and PeptideScanner's reviewed identity mapping was plecanatide.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT05849389 at 2026-07-30T18:43:56.187Z. Its registry update date was 2024-06-24, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05046132 at 2026-07-30T18:45:10.886Z. Its registry update date was 2024-05-03, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗